# US 2010/0167314 A1 · Control of intracellular target molecule by ip3 receptor-binding protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167314 A1
- Document ID: US20100167314A1
- Status: Published application
- Kind: A1
- Application number: 12/293,681
- Filed: 2007-03-20
- Published: 2010-07-01
- Earliest claimed: 2006-03-20
- Assignees: Japan Science and Technology Agency
- Inventors: Katsuhiko Mikoshiba; Hideaki Ando; Akihiro Mizutani
- Web page: https://patentgrep.com/patent/US20100167314A1

## CPC

- C07K 14/47: from mammals
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/12: for cataracts
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a composition comprising an IP3 receptor-binding protein (IRBIT), a nucleic acid that controls the expression and translation of IRBIT, or an antibody against IRBIT for controlling at least one intracellular biological function selected from the group consisting of (1) protein synthesis, (2) phosphatidylinositol metabolism, and (3) intracellular pH.

## Claims

### Claim 1

A composition comprising an IP3 receptor-binding protein (IRBIT), a nucleic acid which controls the expression and translation of IRBIT, or an antibody against IRBIT, wherein the composition is for controlling at least one intracellular biological function selected from the group consisting of:
(1) protein synthesis;
(2) phosphatidylinositol metabolism; and
(3) intracellular pH.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein cytoplasmic mRNA polyadenylation mediated by a cleavage/polyadenylation specificity factor (CPSF) is involved in the protein synthesis.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein intracellular PIP2 synthetase (PIPKII) is involved in the phosphatidylinositol metabolism.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein intracellular p-type Na/HCO3 cotransporter 1 (pNBC1) is involved in the intracellular pH.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the control is suppression or elevation.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the IRBIT is derived from a human or a mouse.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the IRBIT is a protein comprising an amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 3 or a protein which comprises an amino acid sequence having 90% or more identity with said amino acid sequence and has a biological activity equivalent to that of IRBIT.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the composition is used in vivo, in vitro, or ex vivo.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein the composition is for treatment of diseases.

### Claim 10

Use of IRBIT in in vitro or ex vivo control of the synthesis of proteins within cells.

### Claim 11 (depends on 10)

The use according to claim 10, wherein the IRBIT binds to CPSF to control a function of CPSF.

### Claim 12

Use of IRBIT in in vitro or ex vivo control of the metabolism of phosphatidylinositol within cells.

### Claim 13 (depends on 12)

The use according to claim 12, wherein the IRBIT suppresses PIPKII activity.

### Claim 14

Use of IRBIT in in vitro or ex vivo control of a pH within cells.

### Claim 15 (depends on 14)

The use according to claim 14, wherein the IRBIT activates pNBC1.

### Claim 16 (depends on 15)

The use according to claim 15, wherein the activation of the pNBC1 requires phosphorylation of the IRBIT.

### Claim 17

A method for screening for a substance, comprising measuring a binding of IRBIT to CPSF, PIPKII, or pNBC1 in the presence of a candidate substance and then identifying a substance that suppresses or elevates said binding.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the substance is for treatment or diagnosis.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the binding is performed within a mammalian cell.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the substance controls at least one intracellular biological function selected from the group consisting of intracellular protein synthesis, phosphatidylinositol metabolism, and intracellular pH.
